Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Invion ( (AU:IVX) ) has issued an announcement.
Invion Limited has announced the opening of its Entitlement Offer, allowing eligible shareholders to participate in a non-renounceable pro rata offer of Loyalty Options. The offer is part of Invion’s strategic efforts to enhance shareholder value and support its ongoing research and development initiatives in the life sciences sector. This move is expected to strengthen Invion’s financial position and further its capabilities in the development of innovative treatments, thereby potentially impacting its market positioning and stakeholder interests positively.
More about Invion
Invion is a life-science company specializing in the research and development of Photosoft technology, which is used for treating various cancers, atherosclerosis, and infectious diseases. The company holds exclusive rights to this technology in several regions, including Australia, New Zealand, and parts of Asia and Oceania. Invion is listed on the Australian Securities Exchange (ASX: IVX) and is actively involved in developing Photodynamic Therapy (PDT), a less invasive cancer treatment option.
Average Trading Volume: 109,004
Technical Sentiment Signal: Sell
Current Market Cap: A$9.34M
For an in-depth examination of IVX stock, go to TipRanks’ Overview page.